

SINGAPORE
BIOTECH INVEST

21-22 March 2017

Singapore Exchange (SGX)

HONG KONG
BIOTECH INVEST

23-24 March 2017

KPMG Hong Kong

AUSTRALIA-CHINA
BIOTECH INVEST

27-28 March 2017

Shanghai Marriott Hotel City Centre

NOVOGEN COMPANY PROFILE

Novogen Limited (ASX: NRT; NASDAQ: NVGN) is an emerging oncology-focused biotechnology company, based in Sydney. Novogen has a diversified portfolio of four development candidates targeting a range of cancer types.

The lead program, GDC-0084, is being developed to treat glioblastoma, the most common and most aggressive form of brain cancer. Licensed from Genentech in late 2016, GDC-0084 will enter phase II human trials in 2017.

Three further molecules have been developed internally. Cantrixil commenced a phase I human trial in ovarian cancer in December 2016. Anisina and Trilexium are currently in animal testing.

For more information, please visit: www.novogen.com